7 results

• FDA Rejects Nuplazid Application for Treatment of Alzheimer’s Disease Psychosis

  August 8, 2022

  Russell Maas

  The FDA has rejected an application to approve Nuplazid to treat Alzheimer's disease psychosis.

• FDA Rejects Request To Expand Nuplazid Use For Symptoms of Dementia-Related Psychosis

  April 6, 2021

  Irvin Jackson

  Federal health regulators have rejected an application filed by Acadia Pharmaceuticals to expand the use of its blockbuster antipsychotic drug,...

• ISMP Report Questions Nuplazid Safety, FDA Approval And Lack Of Warnings

  March 29, 2019

  Irvin Jackson

  An ISMP report questions the FDA conclusions that there are no new safety signals with the Parkinson's disease psychosis drug, Nuplazid.

• Rexulti Gambling Risks Lead to Concerns About Abilify Replacement Drug

  April 27, 2018

  Irvin Jackson

  New warnings have been added to the warning label for the antipsychotic Rexulti, warning that it carries a risk of gambling addiction, similar to claims made regarding the drug Abilify.

• Nuplazid Safety Risks May Lead FDA To Re-Review New Medication, Gottlieb Tells Senate

  April 26, 2018

  Irvin Jackson

  The FDA has launched a new safety review of the Parkinson's disease drug Nuplazid, FDA Commissioner Scott Gottlieb told Congress last week.

• Nuplazid Problems Linked To Hundreds Of Patient Deaths: Report

  April 11, 2018

  Irvin Jackson

  More than 700 deaths have been linked to Nuplazid side effects, raising concerns about the safety of the Parkinson's disease drug.

• Geodon Side Effects Linked To Potentially Deadly Skin Reactions: FDA

  December 12, 2014

  Russell Maas

  The FDA is warning that side effects of Geodon and generic equivalents of the antipsychotic medication may cause a rare...